Liang Schweizer is the Co-founder, Chairman and Chief Executive Officer of HiFiBiO Therapeutics. Previously, she co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise.

Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizer was a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology (IO) clinical candidates.

Liang Schweizer graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.

Francisco Adrian is the Chief Scientific Officer at HiFiBiO Therapeutics. He is an accomplished scientist with more than 20 years of experience in drug discovery and pharmaceutical research and development.

Previously, Dr. Adrian worked as a Director at the Sanofi Oncology Division, where he led the research efforts for different small molecule and antibody programs in preclinical and clinical development stages. Before joining Sanofi, he was a Group Leader at the Genomics Institute of the Novartis Research Foundation focused on the discovery of novel kinase inhibitors for Oncology indications.

Dr. Adrian graduated in Organic Chemistry and Biochemistry and received his PhD in Molecular Microbiology from the University of Zaragoza, Spain. His postdoctoral training was in Hemato-Immunology at the St Louis Hospital in Paris.

Dr. Luigi Manenti is the Chief Medical Officer at HiFiBiO Therapeutics. He is a seasoned physician scientist with extensive experience designing and executing innovative clinical trials with a strong expertise in translational clinical oncology.

Previously, Dr. Manenti served as the Team Leader for Solid Tumors in Global Pipeline Strategy at Novartis Oncology Business Unit where he oversaw the early commercial and pipeline strategy for various internal and external assets. Prior to this role, he worked at the Novartis Institutes for BioMedical Research as Global Clinical Program Leader, leading multiple programs including capmatinib (Tabrecta) and MBG453 (sabatolimab). His earlier roles include multiple positions at Roche in Switzerland and China including Translational Medicine Site head.

Dr. Manenti holds an MD in Medicine and Surgery from the University of Pavia.

Lynn Bodarky is the Senior Vice President, Global Head of Business Development and Alliance Management at HiFiBiO Therapeutics. She has over 25 years of leadership experience in the global bio-pharma industry spanning corporate strategy, international business development, and finance.

Prior to joining HiFiBiO, Lynn was Vice President, Business Development at Geron where she was responsible for business development including in-licensing, out-licensing, and strategic transaction opportunities. Previously, she was President of LMB Consulting LLC where she provided corporate strategy and end-to-end business development advisory services to biopharmaceutical companies. In her prior executive roles at Intrexon Corporation, Pfizer Inc., Progenics Pharmaceuticals and Merck & Co., Inc. Lynn negotiated and structured corporate and public-private partnerships.

Lynn has a B.S. from The Wharton School, University of Pennsylvania and an M.B.A. from Columbia Business School, Columbia University.

John Pallante is the Vice President, Global Head of Clinical Operations at HiFiBiO Therapeutics. He has over 15 years of clinical operations experience preparing and executing global clinical trials alongside partners and collaborators.

Prior to HiFiBiO, Mr. Pallante served as the Global Head of Clinical Quality Management and Training at Novartis Institutes for BioMedical Research. Before then, he held various leadership roles at Novartis in the areas of Governance and Operational Excellence, Clinical Operations, and Clinical Trial Intelligence.

John Pallante earned his MS from Temple University and BS from Rutgers, The State University of New Jersey-Camden.

Dr. Christos Hatzis is the Vice President, Global Head of Translational Medicine at HiFiBiO Therapeutics. He is an engineer by training with extensive translational and immune-oncology experience and an entrepreneurial mindset.

Prior to HiFiBiO, Dr. Hatzis was a Director, Tumor Strategy Lead, Translational Medicine at Bristol-Myers Squibb where he provided scientific and strategic leadership for the solid tumor programs. Before BMS, he served as an Associate Professor for the Department of Internal Medicine (Medical Oncology) at Yale University School of Medicine, where he still holds an Adjunct faculty position. Earlier in his career, he co-launched two start-up companies, Silico Insights and Nuvera Biosciences, an informatics and data mining company and ventured-funded spin off the MDACC respectively.

Jinping Gan is the Vice President, Global Head of Research at HiFiBIO. He is a biological chemist with 20 years of biopharma industry experience.

Jinping has strong expertise in drug metabolism, pharmacokinetics and pharmacodynamics, and chemical toxicology. Jinping previously worked at Bristol-Myers Squibb, focusing on preclinical optimization and characterization of diverse pipeline molecules from early discovery to NDA filings. Jinping held a PhD in Biological Chemistry from MIT , and a BS in Analytical Chemistry from University of Science & Technology of China.

Edward Rocnik is the Executive Director, Global Head of CMC at HiFiBiO Therapeutics. He is a seasoned scientist with over 12 years of experience in CMC and research related roles.

Previously, Dr. Rocnik has held various CMC and research roles at Takeda, Millennium, and Organogenesis. Most recently, he served as Director, Head of Late-Stage Analytical Development, Cell Therapies at Takeda.

Dr. Rocnik earned his PhD and BS from Western University.

Rachel Yao is the Financial Controller at HiFiBiO Therapeutics and carries extensive knowledge and working experience in finance and audit for the life science industry.

Previously, Rachel worked for Ernst & Young (EY) for more than 11 years, providing multinational clients assurance and services related to Hong Kong capital markets. She is familiar with IFRS/HKFRS reporting framework, IFRS/HKFRS updates and Hong Kong listing rules. Moreover, she served as an EY industry expert on pharmaceutical manufacturing and distribution.

Rachel holds a CPA (Certified Public Accountant) certification from China and Australia and a BS degree in Accounting from Shanghai University of Finance & Economics.

Dr. Steven Chen is the General Counsel at HiFiBiO Therapeutics and leads all legal activities in the company including corporate compliance, IP, and contracting.

Prior to joining, Steven served as the Sr. Patent Attorney at DSM Nutritional Products LLC. At DSM, he helped build a global IP portfolio and secured strategic partnerships for some of the company’s most important products. Before DSM, he spent 5 years at Jones Day LLP, a private legal practice, providing legal services to a broad range of biotechnology and pharmaceutical companies. Prior to entering law school, Dr. Chen conducted bioinformatic research at Vertex Pharmaceuticals.

Steve holds a J.D. from Fordham University in New York, a Ph.D. in Molecular and Cell Biology from the University of Maryland, and a B.S. from Fudan University in China.

Dr. Franklin Jiang is the Senior Director, Global Head of Portfolio and Platform Strategy and leads the company’s engagement with investors, strategic partners, and local government. He also coordinates with global research teams to prioritize and advance the HiFiBiO’s portfolio of therapeutics and DIS™ platform.

Previously, Dr. Jiang served as the Managing Partner for HatChip Capital, the investment arm of the National 5G/digital innovation center in China. He also co-founded and served as COO of Quark Venture, managing its Global Health Science Fund across 25 portfolio companies. Prior to Quark Venture, Frank was appointed CFO and Executive Director of two Canadian TSX-V listed bio-energy companies.

Dr. Jiang holds a PhD in Biochemistry and Biophysics from the University of British Columbia, a MSc in Chemistry and Biochemistry from the University of Regina and his BSc in Biological Science from Shanghai Jiaotong University & East China University of Science and Technology.

Vincent Tse is the Director of Staff and Strategy at HiFiBiO Therapeutics. His professional experience includes R&D Product Development, Business Development, and Strategy Consulting for both small biotech and large pharma.

Vincent previously worked for Genentech, conducting competitive intelligence for the company’s asthma portfolio. Prior to Genentech, he performed Product and Business Development for Armata Pharmaceuticals, an innovative biotech focused on therapeutics against antibiotic-resistant infections. Most recently, he was a strategy and portfolio analysis consultant for IQVIA with diverse engagements in digital therapeutics, rare disease, and oncology.

Vincent earned an MBA from Duke University Fuqua School of Business, an MS in FDA Regulatory Affairs from Northeastern University, and a BS degree in Physiological Science from UCLA.

Dr. Roshan Kumar is the Senior Director, US External Innovation at HiFiBiO Therapeutics. He is a scientist with over 15 years of experience in the study of complex biological systems.

Roshan leads US External Innovation activities to identify high impact partnerships and collaborations for the company’s internal pipeline and DIS™ platform. Dr. Kumar’s previous research was focused on the study of transcriptional regulatory networks in mammalian systems, and on understanding how cellular heterogeneity influences fate decisions in individual pluripotent stem cells.

Dr. Kumar received his PhD in Biochemistry from the Scripps Research Institute and Bachelor’s degrees in Chemistry and Biology from the California Institute of Technology. His postdoctoral studies were performed at the Whitehead Institute for Biological Research at MIT and the Wyss Institute for Biologically Inspired Engineering at Harvard Medical School.

Sami Ellouze is the Director, France General Manager at HiFiBiO Therapeutics. He is an engineer and scientist with over 7 years of experience working with and optimizing single cell technologies for both internal drug discovery programs and external partnerships.

Previously, Sami was involved in NGS data analysis and biomarker identification for a novel metabolomics approach. Sami holds an engineering degree in Conception and Innovation of Bioproducts from the University of Technology of Compiègnem.